Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Sarcoma 37Ovarian Neoplasms 15Leiomyosarcoma 12Liposarcoma 10Neoplasms 7Sarcoma, Ewing 4Neoplasm Metastasis 4Liposarcoma, Myxoid 4Sarcoma, Synovial 3Rhabdomyosarcoma 3Histiocytoma, Malignant Fibrous 3Breast Neoplasms 3Solitary Fibrous Tumors 2Sarcoma, Alveolar Soft Part 2Prostatic Neoplasms 2Osteosarcoma 2Neurofibrosarcoma 2Neoplasms by Site 2Mesothelioma, Malignant 2Malignant mesenchymal tumor 2Ichthyosis, X-Linked 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Fibrosarcoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Bone Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × Trabectedin × Clear all
NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00580112 2014-02-25

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
127 enrolled
Breast

Breast Neoplasms

NCT00050427 2011-04-28

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
53 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡